This medicine is authorised for use in the European Union.


Trecondi is a medicine given to patients before they have a bone marrow transplant from a donor known as ‘allogeneic haematopoietic stem cell transplantation’. It is used as a ‘conditioning’ treatment to clear the patient’s bone marrow and make room for the transplanted bone marrow cells, which can then produce healthy blood cells.

Trecondi is used together with another medicine called fludarabine in adults and children from 1 month of age with blood cancers as well as in adults with other severe disorders requiring a bone marrow transplant.

The active substance in Trecondi is treosulfan.

Haematopoietic stem cell transplantation is rare, and Trecondi was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 23 February 2004.

This EPAR was last updated on 25/01/2023

Authorisation details

Product details
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Hematopoietic Stem Cell Transplantation
Anatomical therapeutic chemical (ATC) code

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
medac Gesellschaft für klinische Spezialpräparate mbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Theaterstrasse 6
22880 Wedel

Product information

10/11/2022 Trecondi - EMEA/H/C/004751 - II/0016

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non malignant diseases, and in paediatric patients older than one month with malignant diseases.

Assessment history

Related content

How useful was this page?

Add your rating
1 rating